These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 28611299)

  • 21. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation.
    Fujiwara M; Anstadt EJ; Clark RB
    Front Immunol; 2017; 8():42. PubMed ID: 28184224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Silencing the expression of Cbl-b enhances the immune activation of T lymphocytes against RM-1 prostate cancer cells in vitro.
    Zhou SK; Chen WH; Shi ZD; Wang SP; Li L; Wen XF; Wang YM
    J Chin Med Assoc; 2014 Dec; 77(12):630-6. PubMed ID: 25249301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Releasing the brake: targeting Cbl-b to enhance lymphocyte effector functions.
    Wallner S; Gruber T; Baier G; Wolf D
    Clin Dev Immunol; 2012; 2012():692639. PubMed ID: 22550535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of exosomal PD-L1 in tumor progression and immunotherapy.
    Xie F; Xu M; Lu J; Mao L; Wang S
    Mol Cancer; 2019 Oct; 18(1):146. PubMed ID: 31647023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
    Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
    MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Control of virus-specific CD8+ T-cell exhaustion and immune-mediated pathology by E3 ubiquitin ligase Cbl-b during chronic viral infection.
    Ou R; Zhang M; Huang L; Moskophidis D
    J Virol; 2008 Apr; 82(7):3353-68. PubMed ID: 18199651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models.
    Willingham SB; Ho PY; Hotson A; Hill C; Piccione EC; Hsieh J; Liu L; Buggy JJ; McCaffery I; Miller RA
    Cancer Immunol Res; 2018 Oct; 6(10):1136-1149. PubMed ID: 30131376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.
    Xiong H; Mittman S; Rodriguez R; Moskalenko M; Pacheco-Sanchez P; Yang Y; Nickles D; Cubas R
    Cancer Res; 2019 Apr; 79(7):1493-1506. PubMed ID: 30679180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Control of NK Cell Activation by Immune Checkpoint Molecules.
    Beldi-Ferchiou A; Caillat-Zucman S
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29023417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions.
    Paolino M; Thien CB; Gruber T; Hinterleitner R; Baier G; Langdon WY; Penninger JM
    J Immunol; 2011 Feb; 186(4):2138-47. PubMed ID: 21248250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymphocyte-activation gene-3, an important immune checkpoint in cancer.
    He Y; Rivard CJ; Rozeboom L; Yu H; Ellison K; Kowalewski A; Zhou C; Hirsch FR
    Cancer Sci; 2016 Sep; 107(9):1193-7. PubMed ID: 27297395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
    Lussier DM; O'Neill L; Nieves LM; McAfee MS; Holechek SA; Collins AW; Dickman P; Jacobsen J; Hingorani P; Blattman JN
    J Immunother; 2015 Apr; 38(3):96-106. PubMed ID: 25751499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of Immune Cell Functions by the E3 Ligase Cbl-b.
    Lutz-Nicoladoni C; Wolf D; Sopper S
    Front Oncol; 2015; 5():58. PubMed ID: 25815272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies.
    Allard B; Allard D; Stagg J
    Methods Mol Biol; 2016; 1458():159-77. PubMed ID: 27581021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cbl-b mediates TGFβ sensitivity by downregulating inhibitory SMAD7 in primary T cells.
    Gruber T; Hinterleitner R; Hermann-Kleiter N; Meisel M; Kleiter I; Wang CM; Viola A; Pfeifhofer-Obermair C; Baier G
    J Mol Cell Biol; 2013 Dec; 5(6):358-68. PubMed ID: 23709694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy.
    Schaer DA; Geeganage S; Amaladas N; Lu ZH; Rasmussen ER; Sonyi A; Chin D; Capen A; Li Y; Meyer CM; Jones BD; Huang X; Luo S; Carpenito C; Roth KD; Nikolayev A; Tan B; Brahmachary M; Chodavarapu K; Dorsey FC; Manro JR; Doman TN; Donoho GP; Surguladze D; Hall GE; Kalos M; Novosiadly RD
    Clin Cancer Res; 2019 Dec; 25(23):7175-7188. PubMed ID: 31409612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon-γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade.
    McNamara MJ; Hilgart-Martiszus I; Barragan Echenique DM; Linch SN; Kasiewicz MJ; Redmond WL
    Cancer Immunol Res; 2016 Aug; 4(8):650-7. PubMed ID: 27262113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.